Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Licenses Roche's qRT-PCR IP for Drug Trials Work

NEW YORK (GenomeWeb News) — Asuragen Pharmacogenomic Services today said it has licensed real-time quantitative PCR technology from Roche Molecular Systems that will enable it to perform clinical gene-expression profiling and DNA analysis.
 
Asuragen said the IP, together with its microRNA and mRNA profiling services, can be used to test predictive biomarker signatures, efficacy markers, and assess patient stratification during clinical drug trials.
 
Financial terms of the agreement were not released.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.